İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi (Dec 2019)
An Investigation into the Role of IGF-1 and IGFBP3 in the Diagnosis and Treatment Response in Esophageal Cancer
Abstract
Aim: Esophageal cancer (EC) is the eighth most common cancer among all cancers worldwide. It constitutes 1.5-2% of all cancers and 5-7% of gastrointestinal cancers. Mortality reduction by early diagnosis, early treatment, and close follow-up is possible in esophageal cancer. However, reliable markers that rapidly provide results for early diagnosis are necessary in order to make such a diagnosis. In our study, it is aimed to investigate the role of IGFBP3 and IGF-1 in the early diagnosis of esophageal tumors. Method: 37 patients with a histopathologically confirmed diagnosis of EC and 41 age- and sex-matched healthy controls were included in our study at Istanbul University Institute of Oncology. Serum IGF-1 and IGFBP-3 levels were determined using enzyme-linked immunosorbent assay (ELISA).Findings: The mean age of the patients included in this study was 54.51±13.69 years. Based on the comparison between the groups, there was no difference in terms of gender and age (p=0.675 and 0.094). There was a statistically significant difference between the control group and the patient group in terms of IGF-1 and IGFBP3 levels. Both levels were higher in the control group (p=0.006, p<0.001). 22 patients had a recurrence. There was no significant difference between the IGF and IGFBP3 levels in those who had a recurrence. 32 patients died. There was no significant difference in terms of the histological subtype, T and pathologic stage of the disease, and IGF-1 and IGFBP3 levels. Conclusion: Our study showed that IGF-1 and IGFBP3 markers could be used in the diagnosis of esophageal tumors. We think that it is necessary to conduct further studies with larger series in order to draw a clear conclusion.
Keywords
